Advances in detection technologies, such as Single-Molecule Array (SIMOA), have enabled precise quantification of low-abundance proteins in biofluids, including Aβ peptides and p-tau, biomarkers relevant to AD. This evidence concerns the gene MAPT and Alzheimer disease.